Targacept Revises Results of Exploratory Study of TC-6987 in Asthma

Targacept has been forced to revise the results of an exploratory phase-II clinical study of TC-6987 after discovering an error in its previous statistical analysis.

Biopharmaceutical company Targacept has announced revised top-line results from an exploratory phase-II clinical trial involving its investigational asthma therapy TC-6987.

Data obtained during the placebo-controlled trial - which was conducted at 23 sites in the US and involved 93 adult patients with mild to moderate asthma - were re-analysed after an error was identified in the application of the statistical analysis plan.

Targacept admitted that the revised results show the therapy did not meet one of its co-primary endpoints.

However, it still met its other co-primary endpoint - change in forced expiratory volume (FEV1) from baseline to two hours post-dosing